Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor RNA-transfected dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- United States Department of Veterans Affairs
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intradermal, Intranodal
01
Overview
This is an investigational autologous cellular immunotherapy developed by the US Department of Veterans Affairs for the treatment of metastatic, androgen-resistant prostate cancer. The vaccine is produced by harvesting a patient's monocytes and differentiating them into dendritic cells (DCs) using cytokines such as GM-CSF and IL-4. These DCs are then transfected with either autologous tumor-derived RNA or RNA from established prostate cancer cell lines (including DU-145, LNCaP, and PC-3). Once administered, these transfected dendritic cells function as professional antigen-presenting cells that prime and activate the patient's cytotoxic T lymphocytes (CTLs) to recognize and attack prostate cancer-specific antigens, most notably prostate-specific antigen (PSA). Clinical trials have demonstrated that the vaccine is safe and capable of inducing robust tumor-specific immune responses.
- Other names
- Tumor RNA Transfected Dendritic Cell VaccineRNA-transfected dendritic cell vaccineVA prostate cancer vaccine
Beyond the preview
Go deeper on autologous tumor RNA-transfected dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor RNA-transfected dendritic cell vaccine.